TY - JOUR T1 - Sarcopenia and Frailty in Chronic Liver Damage: Common and Different Points JF - In Vivo JO - In Vivo SP - 2549 LP - 2559 DO - 10.21873/invivo.12072 VL - 34 IS - 5 AU - HIROKI NISHIKAWA AU - KAZUNORI YOH AU - HIRAYUKI ENOMOTO AU - YOSHINORI IWATA AU - YOSHIYUKI SAKAI AU - KYOHEI KISHINO AU - YOSHIHIRO SHIMONO AU - NAOTO IKEDA AU - TOMOYUKI TAKASHIMA AU - NOBUHIRO AIZAWA AU - RYO TAKATA AU - KUNIHIRO HASEGAWA AU - TAKASHI KORIYAMA AU - YUKIHISA YURI AU - TAKASHI NISHIMURA AU - SHUHEI NISHIGUCHI AU - HIROKO IIJIMA Y1 - 2020/09/01 UR - http://iv.iiarjournals.org/content/34/5/2549.abstract N2 - Aim: To elucidate the common and different points between sarcopenia and frailty in chronic liver damage (CLD). Patients and Methods: Patients with both grip strength decline and skeletal muscle index decline were regarded as sarcopenia. Frailty was defined as a syndrome in which 3 or more of the following criteria were met: i) exhaustion, ii) body weight loss, iii) slow walking speed, iv) muscle weakness, and v) low physical activity. Results: Sarcopenia and frailty were identified in 52 patients (15.2%) and 46 (13.5%), respectively. The prevalence of sarcopenia and frailty was well stratified according to age and the liver cirrhosis (LC) status. In the multivariate analysis, we identified significant factors for sarcopenia: i) age, ii) LC, iii) body mass index and iv) extracellular water (ECW) to total body water (TBW) ratio, while only the ECW to TBW ratio was significant for frailty. Conclusion: Sarcopenia and frailty in CLD should be separately evaluated. ER -